As the 2026 trading year rolls on, I’d like to stop for a moment and say…

What a freakin’ start!

As of last week, Karim and I have put up some of the strongest numbers in the six-year history of The War Room.

So far in 2026, we’ve hit winners on 89 out of 107 total trades, good for an eye-popping 83% win rate and an average return per trade about 14%.

Even better…

We’ve won 25 out of 26 trades so far in April.

So, let’s keep this momentum rolling!

That means diving into some super-speculative positions that could continue to benefit from the current administration’s unique approach to healthcare.

Specifically…

Let’s discuss the reality of the new MAHA movement.

As I’m sure you know, there’s a new White House initiative aimed at accelerating clinical reviews of psychedelics.

On April 18, President Trump signed an Executive Order specifically directing federal agencies to streamline regulatory pathways and expand access to psychedelic medicines for patients where other treatments have failed.

Military veterans suffering from PTSD are at the center of that push.

While unorthodox and super speculative, here are some of the companies that could benefit from any sort of positive sector news in the near term…

AtaiBeckley (ATAI): The result of a $390 million merger between atai Life Sciences and Beckley Psytech that was completed in November 2025, this company is developing a nasal spray using a synthetic form of 5-MeO-DMT. It’s the compound found in the Sonoran Desert toad that Hunter Biden and Mike Tyson have both publicly credited for personal transformations.

The FDA granted the drug Breakthrough Therapy designation in October 2025. Phase 3 trials were initiated in Q2 2026. Shares are already up 196% over the last year.

Compass Pathways (CMPS): It’s working on treatment-resistant depression with a lab-made compound of psilocybin, the active ingredient found naturally in magic mushrooms.

Compass is accelerating its launch timeline by 9 to 12 months after a positive FDA meeting, putting it on track to be the first company with a shot at FDA approval for a psilocybin product in late 2026 or early 2027. Shares are up 117% in the last 12 months.

Definium Therapeutics (DFTX): Formerly known as MindMed, this company rebranded in January 2026 and has a late-stage trial using a pharmaceutical-grade formulation of LSD for depression and anxiety.

Three Phase 3 readouts are coming in the next six months, with MDD data expected late Q2, and two GAD studies reading out in Q3.

They are also studying whether R-MDMA, a form of the party drug Molly, can help patients with autism spectrum disorder. Definium publicly applauded the White House Executive Order two weeks ago and named it a direct catalyst for its pipeline. Shares are up 283%.

Now, before you pull up these tickers and buy…

None of these three companies has any meaningful revenues, but with a more favorable regulatory environment and a White House actively pushing to accelerate psychedelic medicine approvals, I thought I’d bring them to your attention for possible super-speculative upside MAHA plays.

YOUR ACTION PLAN

If any sort of positive news hits the airways on any of these three stocks, you could easily see the upside gains continue.

The near-term binary events to watch are Definium’s three Phase 3 readouts between now and Q3 2026 and any further White House or FDA announcements on psychedelic medicine policy.

Put all three on your speculative watch list for pending news right now!